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Abstract
Background and Objectives: Visceral leishmaniasis (VL) is a common complication in AIDS patients living in Leishmania-
endemic areas. Although antiretroviral therapy has changed the clinical course of HIV infection and its associated illnesses,
the prevention of VL relapses remains a challenge for the care of HIV and Leishmania co-infected patients. This work is a
systematic review of previous studies that have described predictors of VL relapse in HIV-infected patients.
Review Methods: We searched the electronic databases of MEDLINE, LILACS, and the Cochrane Central Register of
Controlled Trials. Studies were selected if they included HIV-infected individuals with a VL diagnosis and patient follow-up
after the leishmaniasis treatment with an analysis of the clearly defined outcome of prediction of relapse.
Results: Eighteen out 178 studies satisfied the specified inclusion criteria. Most patients were males between 30 and 40
years of age, and HIV transmission was primarily via intravenous drug use. Previous VL episodes were identified as risk
factors for relapse in 3 studies. Two studies found that baseline CD4+ T cell count above 100 cells/mL was associated with a
decreased relapse rate. The observation of an increase in CD4+ T cells at patient follow-up was associated with protection
from relapse in 5 of 7 studies. Meta-analysis of all studies assessing secondary prophylaxis showed significant reduction of
VL relapse rate following prophylaxis. None of the five observational studies evaluating the impact of highly active
antiretroviral therapy use found a reduction in the risk of VL relapse upon patient follow-up.
Conclusion: Some predictors of VL relapse could be identified: a) the absence of an increase in CD4+ cells at follow-up; b)
lack of secondary prophylaxis; and c) previous history of VL relapse. CD4+ counts below 100 cells/mL at the time of primary
VL diagnosis may also be a predictive factor for VL relapse.
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Introduction
Visceral leishmaniasis (VL) and human immunodeficiency virus
(HIV) co-infection has emerged as a serious disease pattern [1,2].
HIV infection increases the risk of developing VL by 100 to 2,320
times in endemic areas [3,4] and, on the other hand, VL promotes
the clinical progression of HIV disease and the development of
AIDS-defining conditions [5]. Both infections switch the predom-
inantly cellular immunological response from Th1 to Th2 through
complex cytokine mediated mechanisms leading to a synergistic
detrimental effect on the cellular immune response [6,7,8]. Other
important findings related to HIV-Leishmania co-infection is a
reduction in therapeutic response and high rate of relapse, which is
the clinical deterioration after clinical improvement, observed in
25–61% of patients [9,10,11,12]. Although the term recurrence
has also been used as synonym for relapse, recurrence applies to
the finding of a parasite repeatedly. It is important to emphasize
that neither of these two terms distinguishes parasitological
persistence from re-infection.
The poor therapeutic outcome, the high rate of relapse, the
poliparasitic nature of VL in HIV-infected persons, as well as the
atypical manifestations of the disease and the impaired access to
health-care resources make HIV-infected individuals prone to
enlarge the number of human reservoirs [13]. This concern is of
utmost importance in Asia, where HIV and Leishmania co-
infections are increasingly being reported in countries that are
also facing parasite resistance to antimonial drugs [14].
Recent changes in the epidemiological patterns of HIV and
Leishmania infections are likely to lead to a greater degree of overlap
and greater risk of co-infection and they justify increased alertness.
From a global epidemiologic viewpoint, two parallel trends are
alarming: the ruralization of the HIV pandemic and the
urbanization and spread of VL [1,15]. World Health Organization
(WHO) [16] reports that the public health impact of leishmaniasis
worldwide has been grossly underestimated for many years
because notification was compulsory in only 32 of the 88 countries
where 350 million people were at risk. The reported global
incidence of co-infection is likely underestimated either because
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infection in all endemic areas.
Before the widespread use of antiretroviral therapy, such co-
infection was common in Europe [5]. The co-infection is now
becoming proportionately more prominent in areas with poor
access to antiretrovirals, such as Africa. In areas where it is
available, highly active antiretroviral therapy (HAART) has
changed the course of the HIV/AIDS epidemic and the
outcome of associated opportunistic infections. However,
evidence of relapse rate reduction in patients using HAART
is conflicting [17]. This work is a systematic review of studies
describing the predictors of VL relapse in HIV-infected
patients.
Methods
Search Strategy and Selection Criteria
This review was conducted on all papers published before July,
31, 2010. To ensure scientific rigour, the Preferred Reporting of
Systematic Reviews and Meta-Analysis (PRISMA) guidelines [18]
were used for systematic data synthesis. Studies were identified by
a Medline/PubMed search using a combination of terms that has
been shown to maximize sensitivity [19]. The search terms used
are shown in Figure 1. The LILACS and Cochrane databases
were used for literature review using a Boolean combination of
search terms. Additional reports were located using a manual
search of references from retrieved papers. Two independent
reviewers (GFC and MRS) initially checked the lists of titles and
abstracts identified by this search to determine whether an article
contained relevant data. Studies were considered eligible if they
were presented in an original article, examined HIV-infected
individuals over 14 years of age with a VL diagnosis, included
follow-up after the leishmaniasis treatment and clearly analyzed
predictors of relapse.
There were no restrictions on the publication language, date of
publication, use of secondary prophylaxis, or duration of follow-up
in the study. We excluded studies evaluating fewer than ten cases
and studies evaluating mixed populations of HIV-infected and
uninfected subjects unless separated results for HIV patients were
identified. The selected articles were read in full to confirm
eligibility.
Data were extracted directly from the full-length articles into
structured tables containing all of the descriptive variables and
relevant outcomes. The following information was extracted:
country and period of enrollment; sample size; clinical character-
istics of the included patients; study design; the number of
excluded patients if specified; statistical analyses utilized; duration
of follow-up and number of subjects lost to follow-up; outcome of
interest; prognostic variables assessed in each study and quality of
the regression model [20,21,22]. When data were available tests
required for completion of the tables were performed. To
summarize the results regarding secondary prophylaxis, the
software Comprehensive Meta-Analysis Version 2.2.048 was used.
Author Summary
Visceral leishmaniasis (VL) is the most serious form of an
insect-transmitted parasitic disease prevalent in 70 coun-
tries. The disease is caused by species of the L. donovani
complex found in different geographical regions. These
parasites have substantially different clinical, drug suscep-
tibility and epidemiological characteristics. According to
data from the World Health Organization, the areas where
HIV-Leishmania co-infection is distributed are extensive.
HIV infection increases the risk of developing VL, reduces
the likelihood of a therapeutic response, and greatly
increases the probability of relapse. A better understand-
ing of the factors promoting relapses is essential; therefore
we performed a systematic review of articles involving all
articles assessing the predictors of VL relapse in HIV-
infected individuals older than 14 years of age. Out of 178
relevant articles, 18 met the inclusion criteria and in total,
data from 1017 patients were analyzed. We identified
previous episodes of VL relapse, CD4+ lymphocyte count
fewer than 100 cells/mL at VL diagnosis, and the absence
of an increase in CD4+ counts at follow-up as major factors
associated with VL relapse. Knowledge of relapse predic-
tors can help to identify patients with different degrees of
risk, facilitate and direct prophylaxis choices, and aid in
patient counseling.
Figure 1. Terms used in Medline/PubMed search.
doi:10.1371/journal.pntd.0001153.g001
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Our selection process is illustrated in Figure 2. Of 178 articles,
136 were excluded because they did not meet the inclusion criteria
following reading of titles and/or abstracts. Twenty more articles
were excluded after reading the entire article: six analyzed less
than ten patients [23,24,25,26,27,28,29], one was a review [30],
and thirteen did not evaluate the risk on relapse of different
predictors [3,28,31,32,33,34,35,36,37,38,39,40,41]. Four studies
[42,43,44,45] were excluded because they included cases pub-
lished elsewhere [10,46,47]. Thus, 18 studies (Table S1) satisfied
the specified inclusion and exclusion criteria and constituted the
basis of this investigation.
Studies and Patients
Table S1 summarizes the characteristics of the 1017 patients
encompassed by the 18 included studies. The year of study
publication ranged from 1989 to 2008. The design of 8 of the
studies examined was prospective. Fourteen studies were reported
in Spain, two in Italy, and one in Ethiopia and one in France.
Eight studies had an enrollment period exclusively after 1996,
when HAART became available. Twelve papers stated the
proportions of patients receiving HAART involving two nucleo-
side reverse transcriptase inhibitors and one or two protease
inhibitors or non-nucleosides reverse transcriptase inhibitors at VL
diagnosis or at relapse or both.
A large proportion of the patients in these studies (87.7%) were
male and most were young adults; the median or mean ages
reported varied from 27 to 37 years (Table S2). In the 14 studies in
which patients’ presumed transmission route was known, 72.3%
(420/581) of the infections were likely due to intravenous drug use.
The median CD4+ T lymphocyte count ranged from 11 to 82
cells/mL. Most patients had an AIDS-defining condition [48] at
the time of VL diagnosis (332/572, 58% of patients).
In the majority of the studies, the diagnosis of VL was
established by direct demonstration of amastigotes (by cytological
study of Wright stains) or by the observation of promastigote
growth in samples cultured in specific media. In one study [49],
Figure 2. Study selection process.
doi:10.1371/journal.pntd.0001153.g002
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Leishmania-specific PCR (polymerase chain reaction) of peripheral
blood or bone marrow samples. Three studies [47,50,51] also
included patients diagnosed by serologic tests (direct agglutination,
indirect immunofluorescence or rK-39 dipsticks).
The drug used in the treatment of the primary episode of VL
was reported for 89% of the treated patients. Of this total, 73.4%
of cases (733 patients) were treated with pentavalent antimonial
drugs, 12.4% with amphotericin B deoxycholate (124 patients),
and 2.1% (21 patients) received amphotericin in lipid formula-
tions. A minority of patients (1.2%) received pentamidine
isethionate and three papers included patients treated with
miltefosine [47] or unconventional regimens such as a combina-
tion of allopurinol with an azole compound [50,52]. A test of cure
(staining with Giemsa stain and parasite culture or PCR) at the
end of treatment was carried out in 8 of 18 studies. In most of
these studies, this control was performed for patients whose clinical
response was uncertain. Secondary prophylaxis for leishmaniasis
was reported in eleven studies.
Three studies explored the impact of mono or dual antiretro-
viral therapy at VL diagnosis [47] or during the follow-up [50,53]
on relapse. Only one [47] of these studies demonstrated a
reduction in relapse rate compared with patients who did not
undergo retroviral therapy. Similarly, only one [49] of four studies
[10,49,51,54] that followed patients on HAART at VL diagnosis
reported a reduction in relapse rate. HAART use on follow-up has
also been studied in relation to risk of relapse and none of the five
[9,51,52,54,55] studies showed reduction on VL relapse rate.
Two studies [52,54] that evaluated VL prophylaxis without
specifyingthedrug usednotedasignificantreductioninrelapse.Ina
report of ten cases, Bossolasco et al. [55] showed that the relapse
rate in patients groups with and without prophylaxis were 60% and
100%, respectively, but this difference did not reach statistical
significance. Three studies evaluated specific prophylactic regimens
(antimony compounds [46,50] and liposomal amphotericin [50])
and demonstrated reduction on VL relapse. Although the
confidence intervals did not reach statistical significance, another
author [56] concluded that lipid-complexed amphotericin prophy-
laxis also reduced the relapse rate. Finally, Laguna et al. [57]
showed a trend towards (p=0,08) a reduction in VL relapse rate
following treatment with pentamidine prophylaxis. A meta-analysis
of results from all studies evaluating the impact of secondary
prophylaxis is shown in Figure 3. This analysis could consistently
demonstrate that secondary prophylaxis reduces VL relapse rate.
CD4+ lymphocyte count at VL diagnosis and follow-up has
been studied in relation to risk of relapse. Nine articles
[10,11,12,46,50,51,52,55,58] compared CD4+ lymphocyte cell
counts at VL diagnosis between relapsing and non-relapsing
patients as a continuous variable. Neither of these studies showed
significant differences between these two groups. On the other
hand, two studies [47,49] that compared relapse rate between
patients with CD4+ count at VL diagnosis as a dichotomic
variable (above and below than 100 cell/mL) noted that the arms
with higher CD4+ counts had lower relapse rate. Similarly, an
increase in CD4+ lymphocyte count at follow-up was protective
against VL relapse in 5 of 7 studies [10,11,49,55,58]. In another
study [12], univariate analyses of CD4+ counts at follow-up
revealed a trend towards a reduction in relapse (p=0.09).
Other variables explored in relation to relapse are shown in
Table S3. Factors such as age, route of HIV transmission, history
of intravenous drug use, HIV viral load at VL diagnosis, various
clinical findings, specific anti-Leishmania treatments given, time
from VL diagnosis to the introduction of protease inhibitor
therapy, HAART compliance, the presence of an AIDS-defining
disease before VL diagnosis and the presence of serum anti-
Leishmania antibodies were not substantially different between
relapsing and non-relapsing patients. Tuberculosis co-infection
[47], hepatitis C virus co-infection [49] and an incomplete course
of VL treatment [52] were evaluated in multivariate analysis and
showed a statistically significant association of these conditions
with the occurrence of relapse. Previous VL episodes were
identified as risk factors for relapse in 3 studies, two of which
were multivariate analyses.
Prognostic Variables and Statistical Analysis
The statistical quality and the presentation of methods and
results in many studies were poor. In nine studies, the Kaplan-
Meier method was used in a univariate survival analysis to
Figure 3. Meta-analysis of secondary prophylaxis results. Footnote: I
2=0% Egger test for publication bias was negative, p=0.76.
doi:10.1371/journal.pntd.0001153.g003
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retrospective cohort studies employed Cox regressions for
multivariate analysis of independent predictors. One study
randomized patients to compare prophylaxis (liposomal ampho-
tericin versus no treatment) and performed multivariate analysis to
compare relapse rates by logistic regression, including some
predictors as covariates. None of these six studies mentioned
collinearity assessment (i.e., a high degree of correlation between 2
predictive variables) or developed a risk score for relapse based on
their multivariable results. Also, none of the multivariate analyses
reported a goodness-of-fit test of their models. Other studies
analyzed isolated relapse predictors by univariate association tests
in series of prospective or retrospective cases or in intervention
studies.
Discussion
The present study is the first systematic review of predictors of
VL relapse in HIV-infected patients. Our main conclusions are
that VL relapse in HIV-infected patients receiving HAART is high
and that secondary prophylaxis provides some protective effect but
does not completely prevent the occurrence of relapse. We found
that patients who did not relapse showed significantly higher
CD4+ count at follow-up than patients with relapsing course. Our
analysis also suggests that CD4+ count greater than 100 cell/mL
at VL diagnosis reduces the odds of relapse. Unlike other
opportunistic infections there are some reports of VL relapse in
patients with a CD4+ count greater than 200 cell/mL in Ethiopia,
and rarely in Europe [9]. This evidence shows that factors other
than a CD4+ cell increase are involved in VL control. A threshold
for safely discontinuing of secondary prophylaxis has not been
established because of these uncertainties.
Most cases reported showed severe reductions in T cells. It could
indicate that VL affects HIV-1 patients who exhibit a significant
disturbance of cellular immunity; however, VL by itself may reduce
CD4+ lymphocyte counts [59]. On the other hand, a CD4+ count
greater than 100 cell/mL at VL diagnosis is a potential protective
factor against relapse, although the analysis of this beneficial effect
may be complicated by the immunosuppression of many the
patients included in the studies. When analyzing the CD4+ count
range and number ofpatients with CD4+ countsofgreater than100
cell/mL in the two studies [47,49] demonstrating an association
between higher baseline CD4+ counts and reduced VL relapse, it is
possible to speculate that studies that did not demonstrate an
influence of CD4+ cells had few patients with CD4+ counts of
greater than 100 cell/mL. Studies using animal models reported
that CD4+ cells are responsible for the initial control of parasite
proliferation and dissemination [60]. Thus, a low initial CD4+
count might allow a wide dissemination of the parasite throughout
the phagocytic mononuclear system at the beginning of infection,
increasing the number of sites that could harbor quiescent parasites
(so-called ‘‘sanctuaries’’) [61].
Relapses of VL are suggested to occur mainly in individuals
with poor responses to antiretroviral treatment who have no
improvement in CD4+ counts [11,12,58,62], with a few
exceptions [9,47]. The evolution of patients who acquire VL
and thereafter show a significant increase in CD4+ counts while on
HAART is currently receiving attention [47 50 51 52]. It has
already been established that the outcome of VL is not influenced
by humoral immunity but appears to be regulated by CD4+ T
helper cells with different patterns of cytokine activity [63].
Protective immunity can be attributed to T helper (Th)-1 cells,
whereas Th-2 cell responses produce IL-4 and IL-10 and facilitate
the intracellular survival of the parasite [64]. It might be expected
that highly active antiretroviral drug combinations would favor an
immunological shift from type 2 to type 1 cytokines in HIV-
infected individuals. However, increased CD4+ values in periph-
eral blood and lymphoid tissues as a result of antiretroviral therapy
may have negligible effects on cytokine production during the first
24 weeks [65]. In addition, patients on HAART show an initial
increase in the CD4+ memory subset, whereas naive CD4+ cells
consistently increase only after 1 year [66].
It is known that HIV patients who are receiving HAART have
fewer opportunistic infections and recent data shows that there has
been a decline in the incidence of VL after the introduction of
HAART [41,54,67,68,69]. HAART seems to be insufficient to
prevent VL relapse. Studies in patients receiving HAART showed a
relapse rate similar to other studies performed in the pre-HAART
era. Only one [49] observational study noted a reduction in the
relapse rate among patients on HAART at VL diagnosis. None of
thestudies reported a statisticallysignificantdifferenceinVLrelapse
between patients receiving and not receiving HAART on follow-up.
These disappointing results so far disagree with a statistically
significant association between improvement of CD4+ count at
follow-up and reduction of VL relapse. They may be due to the
small sample sizes of the studies performed, poor patient adherence
to antiviral therapy or insufficient immune response. One possibility
to be explored in the future is the role of cytokines [70] influencing
the control of VL independently of the CD4+ lymphocyte. The
heterogeneity of zymodemes that exhibit different degrees of
virulence or parasite burden could contribute to the differences
observed in the host immune response and clinical evolution [9].
HAART increases CD4+ count thus influencing the control of VL,
but may not be enough in this complex scenario created by the co-
infection HIV and Leishmania. Fernande ´z-Cotarelo et al. [54] and
others [41] have shown a decrease in the number of new episodes of
VL in HIV-infected patients receiving HAART but also a tendency
toward VL relapse. According to these authors the high rates of
relapse could be explained by the increased patient survival that
results from effective antiretroviral therapy.
Previous episodes of VL were strongly associated with relapse.
Also in agreement with the immune-inflammatory theory, it was
hypothesized that the enhancement of the Th-2 response following
one early relapse could complicate or prevent the later control of
Leishmania infection [54].
Secondary prophylaxis seemed to only partially protect against
relapse. Some of studies that observed a reduction in VL relapse
following the use of secondary prophylaxis had few patients on
HAART, which may not reflect the current reality. Data analysis
suggests that the small sample sizes and heterogeneity of regimens
used make the results less robust. Nevertheless, the evaluation of
these studies through meta-analysis indicates a clear benefit of
secondary prophylaxis in reducing VL relapse. Based on six studies
whose data were available, the average relapse rate in patients not
receiving secondary prophylaxis was 67%, while in the secondary
prophylaxis arm, the relapse rate was 31%. Given this difference,
the estimated total sample size needed for a study with 80% power
would be 70 patients. Three out of the six studies examining
secondary prophylaxis were not able to demonstrate statistical
significance,possibly because ofsmallsamplesizes.Itisimportantto
emphasize that despite the heterogeneity of prophylaxis regimens
used; statistical results are positively homogeneous in meta-analysis.
Thresholds for safe discontinuation of secondary prophylaxis for
Spanish patients have been suggested to be CD4+ counts of 200 [71]
and 350 cells/mL [11]. Differently of the European experience, one
Ethiopian study [47] has shown that many patients suffering relapse
(11 from 39 cases) had a CD4+ count above 200 cells/mL before
relapse. These data may suggest that L. donovani,t h ep r e d o m i n a n t
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and anthroponotic species than L. infantum. Another plausible
explanation for this difference may be the influence of other variables
that can affect the host immune response such as nutritional status
and the presence of other infections and co-morbidities.
It has been postulated that the maintenance of an undetectable
viral load protects against the development of VL [17] and that a
high viral load could predict a weak response to antiparasitic
treatment [12] although there are contradictory reports on this
point [54,72]. None of the papers reviewed here linked HIV load
by PCR at VL diagnosis with relapse. On the other hand HIV
load by PCR at follow-up was statistically related to relapse in one
[58] of four studies that evaluated this variable in a univariate
analysis. These observations support the idea that a sustained
immunological response is more important than a virological
response to cure VL in HIV-infected patients.
It is important to note that a wide range of therapeutic drugs
were utilized for the treatment of VL in the studies we have
reviewed. There was no notable difference in the relapse rate with
regard to specific VL treatment used (all analyzed in univariate
analysis); however only four studies explored this association and
most of them included a limited number of patients and only two
[11,73] involved randomly assigned patients. Few comparative
clinical studies have been conducted of the efficacy of treatment
for HIV–VL co-infection outside the Mediterranean area. In some
instances [74,75], the development of drug resistance could
contribute to therapeutic failure and the relapsing course observed
in HIV-infected patients. These observations do not allow us to
refute the influence of anti-parasite treatment on relapse outcome.
Study Limitations
Although we have made an extensive review, our analysis
includes studies with different definitions of cure and different
lengths of follow-up. Cure is seldom defined parasitologically in
these studies and the difference between treatment failure and
relapse is arbitrary in some studies. It is possible that some episodes
of relapse in the group of patients in which parasitological cure
were not documented by bone marrow examination were
treatment failures rather than relapses. Moreover, re-infection
was not distinguished from relapse in any paper. There is a high
degree of heterogeneity in the evaluated populations as shown by
the wide range of reported mortality (6.5% to 83.8%), treatment
failure (0 to 47.6%) and relapse rates (20% to 70%). These studies
included patients with different degrees of immunosuppression,
and different treatment and prophylaxis regimens. Also, there are
differences in the study designs, the types of statistical methods
used and the prognostic variables included in analysis. These
variations may have resulted in patient selection bias or low
statistical power, thus hampering a meta-analysis of all studied
predictors of relapse. In spite of these limitations, we believe that
the meta-analysis results of secondary prophylaxis are consistent,
considering the available evidence. In addition, the quality of
published reports was heterogeneous and usually poor. Despite
these limitations, this review may assist clinicians in making
decisions and may also help in the design of future studies.
Conclusion
The results of this systematic review suggest there are
identifiable predictive factors of VL relapse, such as previous
episodes of VL relapse and lack of recovery of CD4+ lymphocyte
numbers after primary visceral leishmaniasis. HAART did not
produce the anticipated decrease in the incidence of VL relapses
and more data is needed in order to better assess the evolution of
VL in the HAART era. In contrast, secondary prophylaxis was
shown to be protective against relapse. CD4+ count below 100
cells/mL at the time of VL primary diagnosis is a potential
predictor of relapse.
Based on these observations, a high-risk population might be
identified and such patients might then be eligible for secondary
prophylaxis. Strong surveillance will certainly contribute to
improved data quality for decision-makers in this complex
scenario. Randomized trials to compare the efficacy of different
drugs and their role either in treatment or in prophylaxis are
required.
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